Early combination therapy delayed treatment escalation in newly diagnosed young‐onset type 2 diabetes: A subanalysis of the VERIFY study
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
We analysed glycaemic durability (sustained glycaemic control) with early combination therapy (metformin plus vildagliptin) versus metformin monotherapy, among patients with type 2 diabetes diagnosed before (young‐onset [YOD]) and after (late‐onset [LOD]) the age of 40 years, enrolled in the VERIFY trial. The primary endpoint was time to initial treatment failure (TF), defined as HbA1c of 7.0% or higher at two consecutive scheduled visits after randomization. The time to secondary TF was assessed when both groups were receiving and failing on the combination. A total of 186 (9.3%) patients had YOD and 1815 (90.7%) had LOD with a mean age difference of 20.4 years. Compared with metformin monotherapy, early combination reduced the risk of time to initial TF for both YOD (48%, P < .0006) and LOD (46%, P < .0001). With early combination, risk for time to secondary TF was reduced by 48% ( P < .0035) in YOD and 24% ( P < .0009) in LOD. Both treatment approaches were well tolerated with no unexpected safety concerns. In treatment‐naïve patients with YOD (HbA1c 6.5%‐7.5%), an early combination strategy improved attainment of the glycaemic target with durability and delayed treatment escalation compared with initial metformin monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Failure rates in both treatment groups were higher in the EOT2D population compared to the later-onset T2DM population (42.9% with early combination therapy; 61.0% with monotherapy) [65,67].”
From Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions (2025) · cites this paper as [65]
In the citing paper
“In adults with EOT2D, a reduced proportion experienced treatment failure (glycosylated hemoglobin [HbA1c] ≥7.0%) with early combination therapy (metformin and vildagliptin; 50.5%) compared to monotherapy (metformin only; 73.3%) over 5 years.”
From Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions (2025) · cites this paper as [65]
In the citing paper
“Currently, only two RCTs have reported data surrounding the effectiveness of pharmacological treatment in adults with EOT2D in sub-analyses of larger RCTs [65,66].”
From Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions (2025) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“5% above the individualized target, with initial monotherapy combined with lifestyle and dietary restrictions.(16) The marked benefits of an early combination strategy in maintaining glycaemic durability and delaying treatment escalation in newly diagnosed patients with HbA1c of 6.”
BackgroundSelf-citationDiabetes in Asia: Epidemiology, Risk Factors, and Pathophysiology
Chan, J. C. N., Malik, V., Jia, W., Kadowaki, T., Yajnik, C. S., Yoon, K.-H., & Hu, F. B. (2009) · JAMA · doi:10.1001/jama.2009.726 · Cited by 1,997
Self-citation9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s009 · Cited by 914
Polonsky, W., & Henry, R. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s106821 · Cited by 784 · cited 4×
“The lack of long-term efficacy and safety data of pharmacological interventions may contribute towards the delayed treatment initiation and intensification in patients with YOD.(5) Apart from causing long-term complications, the burden of hyperglycaemia can accelerate beta-cell failure, leading to early treatment esca…”
BackgroundInfluentialBuse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetologia · doi:10.1007/s00125-019-05039-w · Cited by 487
Self-citationMatthews, D. R., Paldánius, P. M., Proot, P., Chiang, Y., Stumvoll, M., & Del Prato, S. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32131-2 · Cited by 364 · cited 2×
“Detailed methods of statistical analyses have been reported earlier.(8) Here, we estimated the effect of treatment strategies on time to treatment failures using a Cox proportional hazards regression model.”
MethodResultSelf-citationYeung, R. O., Zhang, Y., Luk, A., Yang, W., Sobrepena, L., Yoon, K.-H., Aravind, S. R., Sheu, W., Nguyen, T. K., Ozaki, R., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70137-8 · Cited by 296
Self-citationβ-cell failure as a complication of diabetes
Chang-Chen, K. J., Mullur, R., & Bernal-Mizrachi, E. (2008) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9101-5 · Cited by 225
Secular trends in incidence of type 1 and type 2 diabetes in Hong Kong: A retrospective cohort study
Luk, A. O. Y., Ke, C., Lau, E. S. H., Wu, H., Goggins, W., Ma, R. C. W., Chow, E., Kong, A. P. S., So, W.-Y., & Chan, J. C. N. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003052 · Cited by 84 · cited 1×
“Kong during 2001-2016, there was an increasing incidence of YOD despite a stable or declining trend in the older age groups.(12) Despite a 50%-70% decline in the death rate over the same period, the age-”
BackgroundSelf-citationCai, X., Gao, X., Yang, W., Han, X., & Ji, L. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0493-2 · Cited by 47 · cited 1×
“5% and older than 50 years.(15) VERIFY is the first study to show the long-term benefits of this treatment approach in newly diagnosed patients over a broad age range with HbA1c of 6.”
Background
Research works printed but not linked: 11
- 10.1016/j.diabres.2017.03.024 · DOI · Paper page
- 10.1016/j.amjmed.2014.03.018 · DOI · Paper page
- 10.1007/s00125-019-05074-7 · DOI
- 10.1186/s12933-019-0916-z · DOI · Paper page
- 10.1111/dom.13800 · DOI
- 10.1016/j.diabres.2015.11.003 · DOI
- 10.2337/dc19-1380 · DOI · Paper page
- 10.7326/M18-1900 · DOI · Paper page
- 10.2337/dc11-s223 · DOI · Paper page
- 10.1056/NEJMoa0806470 · DOI · Paper page
- 10.1007/s00125-012-2827-3 · DOI · Paper page
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Self-citationManagement of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions
Savage, M. J., Goldney, J., Slater, T., Sarkar, P., Sargeant, J. A., Wilmot, E. G., & Davies, M. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0561 · Cited by 11
Metadata
- Authors
- Chan, J. C. N., Paldánius, P. M., Mathieu, C., Stumvoll, M., Matthews, D. R., & Del Prato, S.
- Affiliations
- Department of Medicine & Therapeutics Hong Kong Institute of Diabetes and Obesity and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong China
- Children's Hospital Helsinki University and Helsinki University Hospital Helsinki Finland
- Department of Endocrinology UZ Gasthuisberg KU Leuven Belgium
- Division of Endocrinology and Diabetes University Hospital Leipzig Leipzig Germany
- Oxford Centre for Diabetes, Endocrinology and Metabolism Oxford UK
- Department of Clinical and Experimental Medicine, Section of Metabolic Diseases and Diabetes University of Pisa Pisa Italy
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2020-09-29
- Volume
- 23
- Issue
- 1
- Pages
- 245-251
- ISSN
- 1462-8902
- 1463-1326
- Cited by
- 24
- References
- 10
- Language
- en
- Funders
- Novartis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.